B Cell-Based Treatments in SLE: Past Experience and Current Directions

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
• B cells play a critical role in SLE pathogenesis.
• Targeting B cells represents a novel therapeutic strategy.

Purpose of the Study:

• To review recent data on B cell-targeted therapies in SLE.
• Emphasis on studies published in the last five years.

Main Methods:

• Literature review of recent studies on B cell-targeted therapies in SLE.
• Analysis of clinical trial data and real-world evidence.

Main Results:

• Belimumab, an approved agent, shows increasing positive experience and an acceptable safety profile.
• B cell depletion with rituximab is used worldwide for refractory lupus, yielding promising results despite some negative trial outcomes.
• Targeting autoreactive B cells offers a more rational treatment approach.

Conclusions:

• B cell-targeted therapies, including belimumab and rituximab, are valuable in managing SLE.
• Belimumab is the first approved SLE medication in over 50 years.
• Future research should focus on targeting specific autoreactive B cells for improved SLE treatment.